China National Accord Medicines Corporation Ltd. (000028.SZ)
CNY 29.96
(-0.5%)
CNY 29.96
(-0.5%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 4.03 Billion CNY | -4.88% |
| 2022 | 3.76 Billion CNY | 6.86% |
| 2021 | 3.4 Billion CNY | 8.01% |
| 2020 | 3.29 Billion CNY | 16.79% |
| 2019 | 2.75 Billion CNY | 54.08% |
| 2018 | 1.8 Billion CNY | 16.39% |
| 2017 | 1.55 Billion CNY | -9.84% |
| 2016 | 1.89 Billion CNY | 54.56% |
| 2015 | 1.22 Billion CNY | 7.23% |
| 2014 | 1.08 Billion CNY | 16.28% |
| 2013 | 940.44 Million CNY | 10.95% |
| 2012 | 821.18 Million CNY | 36.38% |
| 2011 | 607.35 Million CNY | 26.79% |
| 2010 | 478.86 Million CNY | 31.98% |
| 2009 | 361.27 Million CNY | 31.2% |
| 2008 | 303.48 Million CNY | 12.12% |
| 2007 | 253.78 Million CNY | 65.09% |
| 2006 | 115.41 Million CNY | 160.84% |
| 2005 | 61.23 Million CNY | 14.29% |
| 2004 | 53.57 Million CNY | 19.52% |
| 2003 | 44.33 Million CNY | 30.93% |
| 2002 | 34.23 Million CNY | -56.61% |
| 2001 | 64.37 Million CNY | 376.99% |
| 2000 | 10.53 Million CNY | 254.11% |
| 1999 | 4.67 Million CNY | 124.66% |
| 1998 | -15.74 Million CNY | 29.94% |
| 1997 | -30.03 Million CNY | -189.28% |
| 1996 | 30.27 Million CNY | 9.59% |
| 1995 | 27.62 Million CNY | -2.79% |
| 1994 | 28.42 Million CNY | 210.93% |
| 1993 | -25.62 Million CNY | -196.58% |
| 1992 | 26.52 Million CNY | -57.48% |
| 1991 | 62.38 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 649.59 Million CNY | -48.31% |
| 2024 Q3 | 465.96 Million CNY | -3.74% |
| 2024 Q2 | 494.72 Million CNY | -10.41% |
| 2023 FY | - CNY | -4.88% |
| 2023 Q1 | 675.82 Million CNY | -26.05% |
| 2023 Q2 | 786.71 Million CNY | 16.41% |
| 2023 Q3 | 621.81 Million CNY | -20.96% |
| 2023 Q4 | 1.08 Billion CNY | 74.99% |
| 2022 Q1 | 493.97 Million CNY | -32.25% |
| 2022 FY | - CNY | 6.86% |
| 2022 Q4 | 913.84 Million CNY | 45.4% |
| 2022 Q3 | 628.51 Million CNY | -19.52% |
| 2022 Q2 | 780.92 Million CNY | 58.09% |
| 2021 FY | - CNY | 8.01% |
| 2021 Q1 | 570.97 Million CNY | -21.37% |
| 2021 Q2 | 759.21 Million CNY | 32.97% |
| 2021 Q3 | 532.47 Million CNY | -29.86% |
| 2021 Q4 | 729.07 Million CNY | 36.92% |
| 2020 Q3 | 587.57 Million CNY | -19.75% |
| 2020 Q2 | 732.2 Million CNY | 55.79% |
| 2020 Q1 | 469.99 Million CNY | -21.31% |
| 2020 Q4 | 726.16 Million CNY | 23.59% |
| 2020 FY | - CNY | 16.79% |
| 2019 Q3 | 529.75 Million CNY | -18.74% |
| 2019 Q4 | 597.26 Million CNY | 12.74% |
| 2019 Q1 | 489.53 Million CNY | -1.01% |
| 2019 Q2 | 651.91 Million CNY | 33.17% |
| 2019 FY | - CNY | 54.08% |
| 2018 Q2 | 620.96 Million CNY | 99.46% |
| 2018 FY | - CNY | 16.39% |
| 2018 Q4 | 494.54 Million CNY | 11.64% |
| 2018 Q3 | 442.99 Million CNY | -28.66% |
| 2018 Q1 | 311.32 Million CNY | -50.03% |
| 2017 Q1 | 315.94 Million CNY | -66.36% |
| 2017 Q2 | 503.67 Million CNY | 59.42% |
| 2017 Q3 | 320.67 Million CNY | -36.33% |
| 2017 FY | - CNY | -9.84% |
| 2017 Q4 | 622.98 Million CNY | 94.28% |
| 2016 Q2 | 447.11 Million CNY | 63.77% |
| 2016 Q4 | 939.31 Million CNY | 290.39% |
| 2016 FY | - CNY | 54.56% |
| 2016 Q1 | 273 Million CNY | -20.95% |
| 2016 Q3 | 240.61 Million CNY | -46.19% |
| 2015 Q3 | 245.45 Million CNY | -16.75% |
| 2015 Q2 | 294.82 Million CNY | 7.63% |
| 2015 Q1 | 273.93 Million CNY | -20.49% |
| 2015 Q4 | 345.37 Million CNY | 40.71% |
| 2015 FY | - CNY | 7.23% |
| 2014 FY | - CNY | 16.28% |
| 2014 Q4 | 344.5 Million CNY | 60.15% |
| 2014 Q3 | 215.11 Million CNY | -24.59% |
| 2014 Q2 | 285.23 Million CNY | 13.07% |
| 2014 Q1 | 252.26 Million CNY | -2.7% |
| 2013 FY | - CNY | 10.95% |
| 2013 Q2 | 206.11 Million CNY | -7.23% |
| 2013 Q1 | 222.17 Million CNY | 21.12% |
| 2013 Q3 | 203.38 Million CNY | -1.33% |
| 2013 Q4 | 259.25 Million CNY | 27.47% |
| 2012 Q3 | 190.85 Million CNY | -14.69% |
| 2012 Q1 | 192.46 Million CNY | 16.24% |
| 2012 Q2 | 223.73 Million CNY | 16.25% |
| 2012 FY | - CNY | 36.38% |
| 2012 Q4 | 183.43 Million CNY | -3.89% |
| 2011 FY | - CNY | 26.79% |
| 2011 Q4 | 165.57 Million CNY | 27.35% |
| 2011 Q3 | 130.01 Million CNY | -6.53% |
| 2011 Q2 | 139.08 Million CNY | -2.89% |
| 2011 Q1 | 143.23 Million CNY | 37.66% |
| 2010 FY | - CNY | 31.98% |
| 2010 Q1 | 95.91 Million CNY | -17.59% |
| 2010 Q2 | 122.41 Million CNY | 27.63% |
| 2010 Q3 | 106.3 Million CNY | -13.16% |
| 2010 Q4 | 104.05 Million CNY | -2.12% |
| 2009 Q4 | 116.38 Million CNY | 94.73% |
| 2009 FY | - CNY | 31.2% |
| 2009 Q2 | 96.24 Million CNY | 46.94% |
| 2009 Q3 | 59.76 Million CNY | -37.9% |
| 2009 Q1 | 65.49 Million CNY | -23.22% |
| 2008 FY | - CNY | 12.12% |
| 2008 Q4 | 85.3 Million CNY | 36.68% |
| 2008 Q3 | 62.41 Million CNY | -8.93% |
| 2008 Q2 | 68.53 Million CNY | 24.1% |
| 2008 Q1 | 55.22 Million CNY | -42.63% |
| 2007 FY | - CNY | 65.09% |
| 2007 Q4 | 96.25 Million CNY | 102.8% |
| 2007 Q3 | 47.46 Million CNY | -5.85% |
| 2007 Q2 | 50.41 Million CNY | 20.68% |
| 2007 Q1 | 41.77 Million CNY | -30.58% |
| 2006 Q2 | 50.39 Million CNY | 71.4% |
| 2006 Q3 | 37.62 Million CNY | -25.34% |
| 2006 FY | - CNY | 160.84% |
| 2006 Q4 | 60.17 Million CNY | 59.95% |
| 2006 Q1 | 29.4 Million CNY | -6.03% |
| 2005 Q3 | 6.34 Million CNY | -68.79% |
| 2005 Q4 | 31.28 Million CNY | 393.07% |
| 2005 Q1 | 14.61 Million CNY | -33.24% |
| 2005 FY | - CNY | 14.29% |
| 2005 Q2 | 20.33 Million CNY | 39.12% |
| 2004 FY | - CNY | 19.52% |
| 2004 Q3 | 10.54 Million CNY | -49.86% |
| 2004 Q2 | 21.03 Million CNY | 182.63% |
| 2004 Q1 | 7.44 Million CNY | -57.59% |
| 2004 Q4 | 21.89 Million CNY | 107.63% |
| 2003 FY | - CNY | 30.93% |
| 2003 Q1 | 6.26 Million CNY | 124.57% |
| 2003 Q2 | 12.49 Million CNY | 99.57% |
| 2003 Q3 | 8.7 Million CNY | -30.32% |
| 2003 Q4 | 17.54 Million CNY | 101.56% |
| 2002 Q1 | 593.95 Thousand CNY | -94.15% |
| 2002 Q4 | 2.78 Million CNY | 154.22% |
| 2002 Q3 | -5.14 Million CNY | -127.86% |
| 2002 Q2 | 18.45 Million CNY | 3007.47% |
| 2002 FY | - CNY | -56.61% |
| 2001 FY | - CNY | 376.99% |
| 2001 Q4 | 10.15 Million CNY | 155.05% |
| 2001 Q3 | -18.44 Million CNY | 0.0% |
| 2000 FY | - CNY | 254.11% |
| 1999 FY | - CNY | 124.66% |
| 1998 FY | - CNY | 29.94% |
| 1997 FY | - CNY | -189.28% |
| 1996 FY | - CNY | 9.59% |
| 1995 FY | - CNY | -2.79% |
| 1994 FY | - CNY | 210.93% |
| 1993 FY | - CNY | -196.58% |
| 1992 FY | - CNY | -57.48% |
| 1991 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Shenzhen Glory Medical Co.,Ltd. | -24.58 Million CNY | 16498.49% |
| Realcan Pharmaceutical Group Co., Ltd. | 387.96 Million CNY | -939.278% |